Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 39,600 shares, a decrease of 8.1% from the May 31st total of 43,100 shares. Based on an average daily trading volume, of 17,500 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.1% of the company’s stock are short sold.

Kamada Stock Up 3.5 %

NASDAQ KMDA traded up $0.17 on Tuesday, reaching $5.00. The company had a trading volume of 16,475 shares, compared to its average volume of 20,434. The stock has a market capitalization of $287.40 million, a P/E ratio of 21.74 and a beta of 1.06. The company’s fifty day moving average is $5.26 and its 200 day moving average is $5.62. Kamada has a 52-week low of $4.08 and a 52-week high of $6.53.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.02). Kamada had a net margin of 8.33% and a return on equity of 5.50%. The business had revenue of $37.74 million for the quarter, compared to analysts’ expectations of $38.01 million. On average, research analysts expect that Kamada will post 0.26 EPS for the current year.

Institutional Investors Weigh In On Kamada

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Aristides Capital LLC grew its stake in shares of Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares during the period. Y.D. More Investments Ltd grew its stake in shares of Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 15,000 shares during the period. Calton & Associates Inc. bought a new position in shares of Kamada during the 4th quarter worth $111,000. Finally, EWA LLC bought a new position in shares of Kamada during the 4th quarter worth $68,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KMDA. StockNews.com began coverage on Kamada in a research report on Thursday, June 27th. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, May 9th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.